Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RG1507 · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RG1507 | DRUG | 16mg/kg, 9mg/kg, 3mg/kg or 1mg/kg iv on Day 1 in one of 4 cohorts of patients |
Inclusion Criteria: * female patients, \>=18 years of age; * invasive, and operable, breast cancer; * ECOG Performance Status of 0 or 1. Exclusion Criteria: * evidence of metastatic disease; * inflammatory breast cancer; * prior hormonal or systemic therapy for breast cancer; * prior treatment wi...
Top 20 of 87 competitors
RG1507 is an investigational small molecule being studied for the treatment of neoplasms, including advanced solid tumors and breast cancer. It has been evaluated in Phase 1 clinical trials in patients with these conditions.
RG1507 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company has sponsored clinical trials of this investigational drug in oncology.
RG1507 is in Phase 1 clinical development. All three of its trials are Phase 1 studies that have been completed. It is an investigational drug and has not been approved by regulatory authorities.
RG1507 has been studied in three completed Phase 1 trials: NCT00400361 in adults with advanced solid tumors, NCT00560144 in children and adolescents with advanced solid tumors, and NCT00882674 in women with operable breast cancer.
Yes, RG1507 is also known as R1507. The clinical trial records use the name R1507, and RG1507 is the same investigational drug being developed by Roche.